Compare Stocks: IKT, ARDX, COLL, and ACHV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.71 -1.1%	$7.16	$2.62 ▼ $8.64	$689.96M	2.42	1.36 million shs	1.09 million shs
ARDX Ardelyx	$3.09 -1.0%	$3.28	$2.80 ▼ $8.40	$784.28M	0.79	4.88 million shs	2.38 million shs
COLL Collegium Pharmaceutical	$25.32 +1.5%	$23.04	$21.43 ▼ $50.79	$775.33M	0.75	644,982 shs	394,691 shs
IKT Inhibikase Therapeutics	$1.52 -0.7%	$1.90	$1.40 ▼ $2.61	$214.61M	0.94	629,775 shs	333,111 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	-0.22%	-3.80%	-11.66%	+42.06%
ARDX Ardelyx	0.00%	+7.29%	-5.50%	-23.89%	-48.84%
COLL Collegium Pharmaceutical	0.00%	+4.58%	+9.23%	-10.31%	-46.53%
IKT Inhibikase Therapeutics	0.00%	+1.33%	-16.94%	-36.93%	-6.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$6.71 -1.1%	$7.16	$2.62 ▼ $8.64	$689.96M	2.42	1.36 million shs	1.09 million shs
ARDX Ardelyx	$3.09 -1.0%	$3.28	$2.80 ▼ $8.40	$784.28M	0.79	4.88 million shs	2.38 million shs
COLL Collegium Pharmaceutical	$25.32 +1.5%	$23.04	$21.43 ▼ $50.79	$775.33M	0.75	644,982 shs	394,691 shs
IKT Inhibikase Therapeutics	$1.52 -0.7%	$1.90	$1.40 ▼ $2.61	$214.61M	0.94	629,775 shs	333,111 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	0.00%	-0.22%	-3.80%	-11.66%	+42.06%
ARDX Ardelyx	0.00%	+7.29%	-5.50%	-23.89%	-48.84%
COLL Collegium Pharmaceutical	0.00%	+4.58%	+9.23%	-10.31%	-46.53%
IKT Inhibikase Therapeutics	0.00%	+1.33%	-16.94%	-36.93%	-6.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.00	Buy	$15.50	131.17% Upside
ARDX Ardelyx	2.92	Moderate Buy	$13.60	340.13% Upside
COLL Collegium Pharmaceutical	2.90	Moderate Buy	$44.88	77.23% Upside
IKT Inhibikase Therapeutics	2.90	Moderate Buy	$4.75	212.50% Upside

Current Analyst Ratings Breakdown

Latest IKT, ARDX, COLL, and ACHV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/12/2026	IKT Inhibikase Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$1.50
11/12/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$8.00
11/9/2026	COLL Collegium Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
11/9/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$14.00 ➝ $11.00
11/6/2026	COLL Collegium Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$35.00
11/6/2026	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$43.00 ➝ $28.00
11/5/2026	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$46.00 ➝ $44.00
11/4/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Strong-Buy
10/23/2026	ACHV Achieve Life Sciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/16/2026	ARDX Ardelyx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/15/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.40 per share	N/A
ARDX Ardelyx	$468.22M	1.66	N/A	N/A	$0.65 per share	4.75
COLL Collegium Pharmaceutical	$780.57M	1.01	$15.44 per share	1.64	$9.54 per share	2.65
IKT Inhibikase Therapeutics	$260K	820.04	N/A	N/A	$1.35 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$54.65M	-$1.55	N/A	N/A	N/A	N/A	-511.12%	-82.35%	N/A
ARDX Ardelyx	-$61.60M	-$0.22	N/A	16.26	N/A	-11.85%	-35.30%	-10.23%	N/A
COLL Collegium Pharmaceutical	$62.87M	$1.00	25.32	4.30	0.78	4.68%	85.14%	13.80%	N/A
IKT Inhibikase Therapeutics	-$48.26M	-$0.40	N/A	N/A	N/A	N/A	-40.53%	-38.44%	N/A

Latest IKT, ARDX, COLL, and ACHV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/10/2026	Q3 2026	ACHV Achieve Life Sciences	-$0.1997	-$0.11	+$0.0897	-$0.11	$10.65 million	N/A
11/10/2026	Q3 2026	IKT Inhibikase Therapeutics	-$0.11	-$0.10	+$0.01	-$0.10	N/A	N/A
11/5/2026	Q3 2026	COLL Collegium Pharmaceutical	$1.86	$1.96	+$0.10	$0.60	$216.03 million	$216.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.87	0.95	0.95
ARDX Ardelyx	1.54	3.45	3.26
COLL Collegium Pharmaceutical	3.44	1.01	0.87
IKT Inhibikase Therapeutics	N/A	15.34	15.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
ARDX Ardelyx	58.92%
COLL Collegium Pharmaceutical	N/A
IKT Inhibikase Therapeutics	3.81%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	1.80%
ARDX Ardelyx	5.30%
COLL Collegium Pharmaceutical	1.85%
IKT Inhibikase Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	28	102.90 million	101.05 million	Optionable
ARDX Ardelyx	489	251.37 million	238.05 million	Optionable
COLL Collegium Pharmaceutical	423	31.08 million	30.50 million	Optionable
IKT Inhibikase Therapeutics	35	140.27 million	130.31 million	N/A

IKT, ARDX, COLL, and ACHV Headlines

Recent News About These Companies

Inhibikase Therapeutics (NASDAQ:IKT) Earns Neutral Rating from Chardan Capital

November 14 at 4:41 AM | americanbankingnews.com

Inhibikase Therapeutics (NASDAQ:IKT) Stock Moved Up to Sell by Wall Street Zen

November 14 at 2:05 AM | americanbankingnews.com

Inhibikase Therapeutics' (IKT) Buy Rating Reaffirmed at HC Wainwright

November 13 at 4:15 AM | americanbankingnews.com

Analysts Offer Insights on NA Companies: Lucid Group (LCID) and Inhibikase Therapeutics (IKT)

November 12 at 3:22 PM | theglobeandmail.com

Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Reaffirmed as Neutral by Chardan Capital

November 12 at 3:11 PM | marketbeat.com

Inhibikase Therapeutics (NASDAQ:IKT) Given Buy Rating at HC Wainwright

November 12 at 8:29 AM | marketbeat.com

Inhibikase Secures 28 Country Approvals For Phase 3 PAH Trial; H1 2027 Safety Update Planned

November 11, 2026 | rttnews.com

Inhibikase Therapeutics (IKT) Q3 2026: EPS Beat Driven by a Larger Share Count

November 11, 2026 | 247wallst.com

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 10, 2026 | marketscreener.comM

Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity

November 10, 2026 | globenewswire.com

Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Lowered by Wall Street Zen

October 31, 2026 | marketbeat.com

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During ...

October 27, 2026 | timesargus.comT

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

October 27, 2026 | globenewswire.com

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Has Consensus Target Price of $4.75

October 23, 2026 | marketbeat.com

Inhibikase Therapeutics, Inc. Announces Board and Committee Changes, Effective October 19, 2026

October 21, 2026 | marketscreener.comM

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

October 20, 2026 | globenewswire.com

Chardan Initiates Inhibikase Therapeutics at Neutral With $1.50 Price Target

October 13, 2026 | finance.yahoo.com

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Nuvation Bio (NUVB)

September 18, 2026 | theglobeandmail.com

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

August 11, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IKT, ARDX, COLL, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$6.70 -0.08 (-1.11%)

Closing price 11/9/2026

Extended Trading

$6.70 0.00 (0.00%)

As of 11/9/2026 07:30 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Ardelyx NASDAQ:ARDX

$3.09 -0.03 (-0.96%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$3.10 +0.02 (+0.49%)

As of 11/13/2026 07:30 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$25.32 +0.37 (+1.48%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$25.36 +0.04 (+0.14%)

As of 11/13/2026 07:30 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Inhibikase Therapeutics NASDAQ:IKT

$1.52 -0.01 (-0.65%)

Closing price 11/13/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 11/13/2026 07:30 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, ARDX, COLL, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, ARDX, COLL, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, ARDX, COLL, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, ARDX, COLL, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, ARDX, COLL, and ACHV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, ARDX, COLL, and ACHV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, ARDX, COLL, and ACHV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IKT, ARDX, COLL, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

Ardelyx NASDAQ:ARDX

Collegium Pharmaceutical NASDAQ:COLL

Inhibikase Therapeutics NASDAQ:IKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools